{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:09:47Z","timestamp":1777421387990,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of subcutaneous tezepelumab in the treatment of severe uncontrolled asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>The PubMed database and ClinicalTrials.gov were searched using the following terms: tezepelumab, Tezspire, AMG157, and MEDI9929.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles published in English between January 2000 and March 2022 related to pharmacology, safety, and clinical trials were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In a phase 2 trial, tezepelumab at low, medium, and high doses reduced the annualized asthma exacerbation rate by 62%, 71%, and 66%, respectively, when compared with placebo ( P &lt; 0.001). In addition to significant reduction of asthma exacerbation rate in the overall treatment population, a phase 3 trial showed significant reduction of asthma exacerbation across all subgroups analyzed regardless of serum eosinophil count (EOS), fractionated exhaled nitric oxide (FeNO) level, or allergic status as determined by IgE sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Tezepelumab is indicated to treat nonallergic and noneosinophilic severe uncontrolled asthma phenotypes in addition to type 2 inflammatory asthma. When selecting the most appropriate biologic agent, consider the risks, benefits, and costs. There is a paucity of data on the efficacy of tezepelumab in patients with comorbid conditions. In the case of a patient presenting with uncontrolled severe asthma with such comorbid conditions, it may be prudent to consider a biologic therapy that can target both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Tezepelumab has shown clinical utility in severe uncontrolled asthma regardless of phenotype, fulfilling the need for treatment options in individuals with severe, uncontrolled, noneosinophilic, and nonallergic asthma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221095540","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T03:30:45Z","timestamp":1652153445000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Tezepelumab in the Treatment of Uncontrolled Severe Asthma"],"prefix":"10.1177","volume":"57","author":[{"given":"Jacqueline","family":"Feist","sequence":"first","affiliation":[{"name":"Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-8247","authenticated-orcid":false,"given":"Melissa","family":"Lipari","sequence":"additional","affiliation":[{"name":"Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences and Ascension St. John Hospital and Medical Center, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences and Ascension St. John Hospital, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"bibr1-10600280221095540","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Accessed February 20, 2022. https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf."},{"key":"bibr2-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042."},{"key":"bibr3-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204114."},{"key":"bibr4-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/361071."},{"key":"bibr5-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00765-2017."},{"key":"bibr6-10600280221095540","unstructured":"Xolair\u00ae (omalizumab). Package insert. South San Francisco, CA: Genentech Inc; 2021."},{"key":"bibr7-10600280221095540","unstructured":"Nucala\u00ae (Mepolizumab). Package insert. Philadelphia, PA: GlaxoSmithKline LLC; 2021."},{"key":"bibr8-10600280221095540","unstructured":"Cinqair\u00ae (Reslizumab). Package insert. West Chester, PA: Teva Respiratory, LLC; 2020."},{"key":"bibr9-10600280221095540","unstructured":"Fasenra\u00ae (Benralizumab). Package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021."},{"key":"bibr10-10600280221095540","unstructured":"Dupixent\u00ae (Dupilumab). Package insert. Tarrytown, NY: Regeneron Pharmaceuticals; 2021."},{"key":"bibr11-10600280221095540","unstructured":"Tezspire\u00ae (Tezepelumab). Package insert. Sodertalje, Sweden: AstraZeneca., Inc; 2021."},{"key":"bibr12-10600280221095540","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094369."},{"key":"bibr13-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-003-0152-0."},{"key":"bibr14-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00226-5."},{"key":"bibr15-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1803."},{"key":"bibr16-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064."},{"key":"bibr17-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.11.014."},{"key":"bibr18-10600280221095540","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S305114."},{"key":"bibr19-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975."},{"key":"bibr20-10600280221095540","unstructured":"Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma (SOURCE). ClinicalTrials.gov identifier: NCT03406078. Updated December 9, 2021. Accessed February 12, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03406078?term=tezepelumab&draw=2&rank=14."},{"key":"bibr21-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01541-7."},{"key":"bibr22-10600280221095540","unstructured":"Long-term Safety of Tezepelumab in Japanese Subjects with Inadequately Controlled Severe Asthma (NOZOMI). ClinicalTrials.gov identifier: NCT04048343. Updated July 2021. Accessed February 12, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04048343."},{"key":"bibr23-10600280221095540","doi-asserted-by":"publisher","DOI":"10.3390\/life11080744."},{"key":"bibr24-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1177\/0194599820965233."},{"key":"bibr25-10600280221095540","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.003."},{"key":"bibr26-10600280221095540","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050819."},{"key":"bibr27-10600280221095540","unstructured":"A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis. ClinicalTrials.gov identifier: NCT03809663. Updated February 21, 2021. Accessed February 20, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT03809663."},{"key":"bibr28-10600280221095540","unstructured":"Efficacy and Safety of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis (WAYPOINT). ClinicalTrials.gov Identifier: NCT04851964. Updated December 23, 2021. Accessed February 20, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04851964."},{"key":"bibr29-10600280221095540","unstructured":"Study to Evaluate Tezepelumab in Adults with Chronic Spontaneous Urticaria (INCEPTION). ClinicalTrials.gov Identifier: NCT04833855. Updated February 11, 2022. Accessed February 20, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04833855."},{"key":"bibr30-10600280221095540","unstructured":"Anti-TSLP (AMG 157) Plus Antigen Specific Immunotherapy for Induction of Tolerance in Individuals with Cat Allergy. ClinicalTrials.gov Identifier: NCT02237196. Updated May 6, 2020. Accessed February 20, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT02237196."},{"key":"bibr31-10600280221095540","unstructured":"Tezepelumab COPD Exacerbation Study (COURSE). ClinicalTrials.gov Identifier: NCT04039113. Updated February 9, 2022. Accessed February 20, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04039113."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221095540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221095540","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221095540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:50Z","timestamp":1777375010000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221095540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10600280221095540"],"URL":"https:\/\/doi.org\/10.1177\/10600280221095540","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]}}}